ExodusPoint Capital Management’s Pyxis Oncology PYXS Stock Holding History

ExodusPoint Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-317,769	Closed	-$365K	–	1995
2025 Q4	$365K	Buy	+317,769	New	+$1.12M	﹤0.01%	1263
2024 Q3	–	Sell	-114,387	Closed	-$379K	–	2007
2024 Q2	$379K	Buy	114,387 +24,916	+28%	+$105K	﹤0.01%	1271
2024 Q1	$381K	Buy	+89,471	New	+$376K	﹤0.01%	1203
2023 Q4	–	Sell	-415,072	Closed	-$826K	–	1944
2023 Q3	$826K	Buy	415,072 +155,511	+60%	+$360K	0.01%	1025
2023 Q2	$664K	Buy	259,561 +189,561	+271%	+$601K	0.01%	1250
2023 Q1	$281K	Buy	+70,000	New	+$140K	﹤0.01%	1483
2022 Q1	–	Sell	-249,762	Closed	-$2.74M	–	2585
2021 Q4	$2.74M	Buy	+249,762	New	+$2.86M	0.03%	633

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ExodusPoint Capital Management's PYXS Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Pyxis Oncology (PYXS) in Q1 2026, closing a stake of 317,769 shares — an estimated $365K sold.

ExodusPoint Capital Management first reported a position in PYXS in Q4 2021 and held it in 7 quarters. The position peaked at $2.74M in Q4 2021. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

ExodusPoint Capital Management reported no remaining Pyxis Oncology position as of Q1 2026 after selling out during the quarter.
ExodusPoint Capital Management sold 317,769 Pyxis Oncology shares in Q1 2026, an estimated $365K.
ExodusPoint Capital Management first reported a position in Pyxis Oncology in Q4 2021 and held it in 7 quarters.
ExodusPoint Capital Management's Pyxis Oncology position peaked at $2.74M in Q4 2021.
78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.